Release date: 2015-09-15

The National Health and Family Planning Commission held a regular press conference on September 10. Qin Huaijin, director of the Science and Education Department of the National Health and Family Planning Commission, pointed out that since the "Twelfth Five-Year Plan", China has closely organized a number of key projects such as major science and technology projects in the field of medicine and health, focusing on national strategies and people's health needs. 30 billion yuan has produced a large number of achievements with international standards.

Medical SCI journal papers rank second in the world

Qin Huaijin said that from 2010 to 2014, the total number of medical SCI journals in China exceeded 230,000, ranking second in the world. Since 2011, the number of medical patent applications has ranked first in the world; genomics, stem cells, immunology The basic research fields have reached the international advanced level, laying a solid foundation for disease diagnosis and control technology and product development. The development of medical and health science and technology has promoted the development of the pharmaceutical industry and provided strong support for solving major health problems and improving health.

In the prevention and treatment of major non-communicable diseases, China's key disease diagnosis and treatment technologies have made great progress, and the technologies and strategies for disease prevention, diagnosis, treatment and rehabilitation have been continuously updated to reduce the incidence, achieve early diagnosis and treatment, improve the treatment effect, and alleviate patients. Pain and economic burdens provide a steady stream of new technologies, new drugs, new methods, and new strategies.

In the prevention and treatment of cardiovascular and cerebrovascular diseases, the cohort study of cardiovascular and cerebrovascular diseases has made a breakthrough, and explored a set of hypertension control, stroke prevention treatment and management mode suitable for the characteristics of our population. In the field of craniocerebral surgery, a number of key technological breakthroughs have been made to further optimize surgical treatment programs, such as brainstem tumors and other difficult brain disease surgical methods, which have significantly improved patient survival and quality of life, and brought China's neurosurgery into the world's leading ranks.

In the aspect of cancer prevention and treatment, we focus on strengthening lung cancer, liver cancer, esophageal cancer, leukemia, etc., and strengthen the research and development of early diagnosis technology, improve the rate of early diagnosis; develop a number of clinical diagnosis and treatment specifications and key technologies to standardize and standardize treatment. The degree of change has been greatly improved. After years of research, Academician Wang Zhenyi proposed the acute differentiation of acute promyelocytic leukemia, and pioneered the combination of trans-retinoic acid and arsenic oxide in the treatment of acute promyelocytic leukemia, which increased the five-year survival rate to 95%. Acute promyelocytic leukemia becomes the first curable adult leukemia.

85 innovative drugs have been approved for diseases such as malignant tumors

Qin Huaijin said that China's prevention and control capabilities have been further enhanced for infectious diseases. Since the "11th Five-Year Plan", China has focused on major infectious diseases such as AIDS, viral hepatitis and tuberculosis, and has continuously increased scientific and technological efforts, and has made series in new diagnostic technologies, optimized clinical treatment programs, comprehensive prevention and control strategies and measures. Breakthrough provides technical support for reducing the rate of new infections and mortality.

The self-developed HIV nucleic acid detection reagent in China has shortened the detection window period from 22 days to 11 days. It has been put into use in the national blood station, effectively improving the blood safety guarantee capability and playing a role in the early detection and control of HIV-infected people. Important role; in order to solve the problem of high mortality of severe liver disease, the artificial liver system independently developed in China reduced the mortality rate of acute and subacute severe hepatitis from 88% to 21%, and the mortality rate of chronic severe hepatitis decreased from 85% to 57%. The new rapid detection reagent for Mycobacterium tuberculosis increases the detection rate by 20%.

In response to the frequent occurrence of new infectious diseases, difficulties, serious harms, and lack of means of prevention and control, China has strengthened its technical system and capacity building, and built a nationwide “response system for the prevention and control of new infectious diseases”. Breaking through key technologies such as pathogen combination screening, the detection and identification capabilities of newly-emerging infectious disease pathogens have reached the international advanced level, and established technical platforms for emergency drug and vaccine research and development, emergency treatment, etc., which have significantly improved the emergency response of sudden outbreaks. Ability to achieve a transition from reactive to proactive.

Qin Huaijin said that the development of science and technology has also promoted the improvement of drug innovation capabilities. China adheres to the clinical drug and industrial development needs as the guide, organizes and implements major new drug creation technology major projects, and continues to strengthen the drug research and development technology system construction, enhance the ability of independent innovation, focusing on malignant tumors, cardiovascular and cerebrovascular infections 10 kinds of diseases such as sexual diseases, adopting the combination of production, study and research to accelerate the innovation and research and development of drug varieties. A total of 85 innovative drugs have been approved, and more than 200 new drug varieties are in clinical trials.

For example, the targeted new drug for the treatment of non-small cell lung cancer, ectinib, the new drug for treatment of advanced gastric cancer, apatinib, and the new drug for the treatment of peripheral T-cell lymphoma, have been successfully marketed, filling the clinical Blank; internationally the first successful development of Sabin strain polio inactivated vaccine, H1N1 influenza vaccine, hepatitis E vaccine, etc., providing new means for prevention and control of infectious diseases; completing a number of imitation innovations of major disease treatment drugs And industrialization, greatly reduced the cost of clinical treatment; technically modified more than 200 kinds of large-scale drugs, improved drug quality, reduced production costs, and significantly improved access to clinical drugs.

Hypertension community management has covered 85 million patients

Gao Fu, deputy director of the Chinese Center for Disease Control and Prevention and academician of the Chinese Academy of Sciences, said that China has implemented effective antiviral treatment programs for children, and the virological success rate of treatment for 12 months is 72.5%. Improve the dose of hepatitis B vaccine, so that the hepatitis B surface antigen carrying rate of children under 5 years old can be reduced to less than 1%, and reach the goal of hepatitis B prevention and control in WHO West Pacific area 3 years ahead of time; successful development of 60 micrograms of hepatitis B vaccine, the vaccination response rate is 78.6 % increased to 92.8%.

The prevalence and mortality rate of infectious tuberculosis was significantly lower than that in 1990, reaching the staged targets of the United Nations Millennium Development Goals in advance; successful development of rapid detection reagents for Mycobacterium tuberculosis significantly improved the detection rate of tuberculosis; establishing research in some areas Demonstration area, actively explore new modes of comprehensive science and technology prevention and control.

Wang Mingrong, deputy director of the National Cancer Center and vice president of the Cancer Hospital of the Chinese Academy of Medical Sciences, said that the research and development of innovative drugs such as molecular targeted drugs in China has been vigorously carried out, and several new anti-tumor drugs have been approved for marketing. For example, gemcitabine hydrochloride, which is used to treat lung cancer, pancreatic cancer, etc., has the same therapeutic effect and is only half the price of imported drugs. It not only benefits many patients in China, but has also been exported to many countries including the United States.

Ecetinib hydrochloride, which treats lung cancer, is the world's third and Asia's first listed lung cancer targeted anticancer drug, breaking the monopoly of imported targeted drugs and lowering the price of imported drugs by 30%-40%. To allow more lung cancer patients to use targeted anticancer drugs, the disease control rate is about 80%, the treatment efficiency is about 30%, and the average survival time is extended from the original 3-6 months to more than one year.

Wang Mingrong said that there are still many targeted drugs in clinical trials in China. In the next three to five years, there will be many domestic targeted drugs coming out, breaking the monopoly of Western targeted drugs, lowering prices, and benefiting more patients.

Gu Dongfeng, deputy director of the National Cardiovascular Center and vice president of Fuwai Hospital of the Chinese Academy of Medical Sciences, said that the National Cardiovascular Center launched the “National Hypertension Community Standardized Management” project in 2005 to promote the popularization of hypertension prevention guidelines. The community conducts standardized management of hypertension and manages a total of 3 million patients.

After 1 year of standardized management, the rate of hypertension control increased from 18.7% at baseline to 76.6%. Since 2009, the state has included the management of hypertension in the content of public health equalization services, and promoted the management of hypertension community throughout the country. As of now, it is estimated that more than 85 million patients are managed.

Source: People's Daily

Manual Video Measuring Instrument

Manual Video Measuring Instrument,Video Device,Fully Automatic Image Measurement ,Optical Measuring Instrument

Zhejiang dexun instrument technology co., ltd , https://www.dexunmeasuring.com